Researchers from Rice University have created drug-filled microparticles that can be engineered to degrade and release their therapeutic cargo days or weeks after administration. By combining multiple microparticles with different degradation times into a single injection, the researchers could develop a drug formulation that delivers many doses over time.
More by Karen Olsen
NIH-funded researchers developed an online tool that can analyze self-collected, at-home videos with a smartphone. When deployed in a nationwide study, the tool could predict physical health and osteoarthritis of the knee or hip.
Researchers at Carnegie Mellon University are developing lipid nanoparticles that are designed to carry mRNA specifically to the pancreas. Their study in mice could pave the way for novel therapies for intractable pancreatic diseases, such as diabetes and cancer.
Bioengineers from Columbia University are developing a pipeline to systematically evaluate how bacterial treatments might synergize with existing anti-cancer therapies in preclinical models.
After years of research, an NIH-funded team has developed a wearable cardiac ultrasound imager that can non-invasively capture real-time images of the human heart. The prototype patch, which is about the size of a postage stamp, can be worn during exercise, providing valuable cardiac information when the heart is under stress.
Using state-of-the-art imaging technology, NIH-funded researchers have found the secret behind the glassfrog’s ability to become transparent, an effective form of camouflage. Future research may provide insights into disorders related to blood clotting or stroke in humans.
NIBIB-funded researchers are developing a new method to treat pancreatic cancer. In their study, they combined an injectable radioactive gel with systemic chemotherapy in multiple mouse models of the disease. The treatment resulted in tumor regression in all evaluated models, an unprecedented result for this genetically diverse and aggressive type of cancer.
NIBIB-funded researchers are fine-tuning a wearable, cuffless blood pressure monitor. Made of graphene, one of the thinnest materials in the world, the device is worn on the underside of the wrist and can measure blood pressure with comparable accuracy to a standard blood pressure cuff.
Researchers have found that AI models could accurately predict self-reported race in several types of medical images, suggesting that race information could be unknowingly incorporated into image analysis models.
NIBIB-funded researchers have developed an interlinked tissue chip system that can model four mature organs in their perspective environments simultaneously. These multi-organ tissue chips could represent a new way to evaluate diseases or drugs that affect multiple different tissues.
Minority patient groups may receive less supplemental oxygen in the ICU due to inaccurate readings from pulse oximeters.
Osteoarthritis – a painful condition that results from the deterioration of the cartilage in our joints – affects millions of people worldwide. To combat this issue, NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment.
NIBIB-funded researchers are developing an imaging method that would allow surgeons to better identify cancerous cells in breast tumor margins during surgery. This technique could lead to a reduction in follow-up breast cancer surgeries and reduce rates of breast cancer recurrence.
NIBIB-funded researchers are developing an autonomous robot that can perform bowel surgery with minimal assistance from a surgeon. In preclinical models, the robot outperformed expert surgeons when compared head-to-head.
NIBIB-funded researchers are developing a method to activate natural killer cells using an external magnetic field, which not only enhances their cytotoxicity, but allows them to be tracked using magnetic resonance imaging (MRI) to verify that they’ve reached their target.